WCN26-2002 SYNERGISTIC ERYTHROPOIETIC EFFECTS AND SAFETY PROFILE OF PEGMOLESATIDE COMBINED WITH ROXADUSTAT IN PRECLINICAL MODELS OF CHRONIC KIDNEY DISEASE-ASSOCIATED ANEMIA

Read full text Summarise with VIRAT
Authors: Xiaoying Ma, Hui Qian, Yuanfeng Zhou, Meixiang Cai, Yunfan Li, Jinwei Dai, Mingjie Luo, Zhizhen Hu, Yongzhen Xiao, Weili Luo
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

In China, chronic kidney disease (CKD)-associated anemia poses a significant clinical burden, with observational studies indicating suboptimal Hb target achievement rates despite guideline-directed therapies. To address persistent Hb maintenance challenges, clinicians increasingly adopt combination strategies pairing erythropoiesis-stimulating agents (ESAs) with hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). However, critical gaps exist in preclinical evidence supporting this practice.

Fields of Study & Subjects

Erythropoietin and Anemia Treatment Iron Metabolism and Disorders Hemoglobinopathies and Related Disorders

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104193–104193
Publication date
25 March 2026
Language
EN